Financing ·
NRx Pharmaceuticals reported a net loss of $18.0 million for the six months ended June 30, 2026, compared to $23.1…
NRXPWNRX Pharmaceuticals, Inc.
NRx Pharmaceuticals reported a net loss of $18.0 million for the six months ended June 30, 2026, compared to $23.1 million in the prior year period. The company closed an underwritten public offering of common stock with gross proceeds of $22.3 million, bringing cash and cash equivalents to approximately $26.7 million as of June 30, 2026. Key operational milestones include receiving a complete response letter for its ANDA for preservative-free ketamine (NRX-100) with only a minor packaging deficiency remaining, initiating commercial-scale manufacturing of five million launch doses, and being selected by DARPA as prime contractor for the SPARC-TMS trial with anticipated non-dilutive funding exceeding $11.5 million. The company also appointed Glenn Tyson as its first Chief Commercial Officer to support the anticipated 2026 commercialization of ketamine. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for central nervous system disorders.